Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00612573 · ClinicalTrials.gov registry record · Phase 2
Treatment of Moderate to Severe Facial Acne Vulgaris
A Phase 2 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 2
- Development phase
- 257
- Enrollment target
NCT00612573 is a Phase 2 study that has completed, run by Warner Chilcott. The registered enrollment target is 257 participants.
The verdict
NCT00612573, a Phase 2 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 257 participants
- Enrollment target
Study Summary
Randomized, multi-center, double-blind, placebo-controlled 12-week study to assess the safety and efficacy of 3 doses of an oral formulation of Doxycycline oral tablets using the Investigator's Global Assessment (IGA) score and the absolute change from baseline in inflammatory lesion count in patients with moderate to severe facial acne vulgaris. Additionally, the absolute change from baseline in non-inflammatory and total lesions of the active study medication to placebo will be evaluated.
Interventions
- DRUG Placebo
- DRUG Doxycycline 0.6 mg/kg/day
- DRUG Doxycycline 1.2 mg/kg/day
- DRUG Doxycycline 2.4 mg/kg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 257 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00612573
The ClinicalTrials.gov registry entry for NCT00612573 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 257 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00612573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00612573 about?
NCT00612573 is a clinical study titled "Treatment of Moderate to Severe Facial Acne Vulgaris". Randomized, multi-center, double-blind, placebo-controlled 12-week study to assess the safety and efficacy of 3 doses of an oral formulation of Doxycycline oral tablets using the Investigator's Global Assessment (IGA) score and the absolute change from baseline in inflammatory lesion count in patien...
What is the current status of trial NCT00612573?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 257 participants. The study started on 2008-02. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00612573?
The interventions under investigation include: Placebo (DRUG), Doxycycline 0.6 mg/kg/day (DRUG), Doxycycline 1.2 mg/kg/day (DRUG), Doxycycline 2.4 mg/kg/day (DRUG).
Who is sponsoring clinical trial NCT00612573?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.